Introduction





Products Description
#### 1. Overview and Background
Cialis (generic name: Tadalafil) is a selective phosphodiesterase 5 (PDE5) inhibitor developed by Eli Lilly and Company of the United States. It was first approved in 2003 for the treatment of male erectile dysfunction (ED). Its long-term effect (half-life of about 17.5 hours) and lack of dependence on diet make it a revolutionary drug in the field of ED treatment. In addition, tadalafil is also approved for the treatment of benign prostatic hyperplasia (BPH) and pulmonary arterial hypertension (PAH).
**CAS number**: 171596-29-5
**Molecular formula**: C₂₂H₁₉N₃O₄
**Molecular weight**: 389.41 g/mol
**Chemical name**: (6R,12aR)-6-(1,3-benzodioxolan-5-yl)-2-methyl-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyridino[3,4-b]indole-1,4-dione
#### 2. Chemical properties and structural characteristics
1. **Physical and chemical properties**
- **Appearance**: White to off-white crystalline powder.
- **Solubility**: Almost insoluble in water (<0.1 mg/mL), easily soluble in organic solvents such as dichloromethane and methanol.
- **Stability**: Stable in dry and dark conditions, sensitive to heat, and needs to be stored away from light (refrigerated at 2-8℃ is recommended).
- **Chiral center**: Contains two chiral centers (6R, 12aR), and the stereochemical structure directly affects the efficacy.
2. **Structural advantages**
- **Benzodioxolane group**: Enhances the selective inhibition of PDE5 and reduces the side effects of PDE6 (retina-related).
- **Methylpiperazine ring**: Prolongs the half-life of the drug and supports once-daily dosing.
#### 3. Production process and technical route
1. **Mainstream synthesis route**
- **Route 1 (classical method)**: Using D-tryptophan as the starting material, it is synthesized through 12 steps of reactions such as cyclization, condensation, and chiral resolution.
- **Key intermediates**: Methylpiperazine derivatives, chiral indole ring construction.
- **Challenges**: Complex chirality control and low total yield (about 15%).
- **Route 2 (improved method)**: Using asymmetric catalytic technology, shorten the steps to 8 steps, and increase the yield to 25%-30%.
- **Innovation**: Use palladium catalyst to achieve stereoselective synthesis and reduce the separation steps.
2. **Process optimization direction**
- **Green chemistry**: Reduce the use of toxic reagents (such as thionyl chloride) and use bio-enzyme catalysis.
- **Continuous flow reaction**: Improve reaction efficiency and reduce batch differences.
#### 4. Quality control and testing standards
1. **Pharmacopoeia standards**
- **USP/EP/ChP**: Purity ≥ 99.0%, total impurity ≤ 0.5%, single unknown impurity ≤ 0.1%.
- **Key test items**:
- **HPLC**: Analysis of main component content and impurity spectrum.
- **Chiral HPLC**: Ensure enantiomeric purity (R, R configuration ≥ 99.5%).
- **Residual solvents**: Meet ICH Q3C standards (such as methanol ≤ 3000 ppm).
2. **Stability study**
- **Accelerated test**: 6 months at 40℃/75% RH, the degradation product does not exceed 0.2%.
- **Photostability**: After exposure to 4500 Lux light, the color change must meet the standard.
#### 5. Pharmacological effects and clinical applications
1. **Mechanism of action**
- **PDE5 inhibition**: Blocks cGMP degradation, enhances NO-mediated vasodilation, and promotes penile corpus cavernosum congestion.
- **Long-acting**: Half-life is 17.5 hours, the efficacy can last for 36 hours, and it supports on-demand or daily low doses (2.5-5 mg).
2. **Indications and dosage forms**
- **ED treatment**: 10/20 mg tablets, taken 30 minutes before sexual activity.
- **BPH combination therapy**: Combined with α-receptor blockers (such as tamsulosin) to relieve lower urinary tract symptoms.
- **PAH indication**: 40 mg once daily, improves exercise capacity (FDA approved in 2009).
3. **Advantage comparison (vs. sildenafil)**
- **No effect of diet**: Not affected by high-fat diet.
- **Lower side effects**: The incidence of headache and hot flashes is 30% lower than that of sildenafil.
- **Sustained efficacy**: Suitable for spontaneous intimacy, reducing time pressure.
#### 6. Market and industry development
1. **Market size**
- **Global ED drug market**: The valuation in 2023 is about 5 billion US dollars, and tadalafil accounts for more than 40%.
- **Generic drug competition**: After Eli Lilly's patent expires (Europe and the United States in 2017, China in 2019), India's Sun Pharma, China's Hausen Pharmaceuticals, etc. have seized the market.
2. **API supply chain**
- **Major manufacturers**: India's Aurobindo, Dr. Reddy's, China's Tianyu Pharmaceuticals, and Huahai Pharmaceuticals.
- **Cost control**: Chinese manufacturers have the advantage of self-production of intermediates, and their costs are 15%-20% lower than those in India.
#### 7. Regulations and environmental requirements
1. **GMP compliance**
- **FDA/EMA on-site inspection**: Focus on cross-contamination control (especially co-production with hormone products).
- **Data integrity**: Electronic records are required to comply with 21 CFR Part 11 standards.
2. **Environmental challenges**
- **Wastewater treatment**: Nitrogen-containing heterocyclic organics need to be degraded by advanced oxidation (AOPs).
- **Solvent recovery**: The recovery rate of dichloromethane must reach more than 95%, in compliance with REACH regulations.
#### 8. Future trends and R&D directions
1. **New dosage form development**
- **Oral dissolving film**: Improve patient compliance and have entered Phase III clinical trials.
- **Transdermal patch**: Avoid first-pass effect and extend release time.
2. **Exploration of new indications**
- **Raynaud's phenomenon**: In Phase II trials to improve peripheral circulation.
- **High altitude pulmonary edema**: Potential application based on its pulmonary artery vasodilation effect.
3. **Green synthesis breakthrough**
- **Biosynthesis**: Using engineered yeast to express key enzymes to achieve whole-cell catalysis.
#### Conclusion
The technical barriers and market demand of tadalafil API jointly promote the upgrading of its industrial chain. With the optimization of processes, the expansion of new indications and the improvement of environmental protection requirements, this field will continue to attract R&D and capital investment, providing safer and more efficient treatment options for patients around the world.
Supported Payment Methods And Contact Us
Supported payment methods
We support multiple payment methods





Contact Us
You can contact us via WhatsApp, Telegram, Gmail, Proton Mail, etc.





Hot Tags: raws powder cialis (tadalafil) improve erectile function cas:171596-29-5, China raws powder cialis (tadalafil) improve erectile function cas:171596-29-5 manufacturers, suppliers, factory, Testosterone Decanoate, Testosterone Acetate, Testosterone Sustanon and SUS250, Testosterone Propionate CAS 57 85 2, Clostebol Acetate, Clostebol Acetate Promotes Protein Synthesis and Boosts Muscle Mass
